Triple Negative Breast Cancer

Showing NaN - NaN of 39

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer Trial in United States (PRO1184)

Recruiting
  • Ovarian Cancer
  • +8 more
  • Scottsdale, Arizona
  • +11 more
Jan 31, 2023

Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)

Recruiting
  • Triple Negative Breast Cancer
  • +14 more
  • LYL797
  • Scottsdale, Arizona
  • +10 more
Jan 30, 2023

Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer Trial in New York, Fairfax, Spokane (XMT-1660)

Recruiting
  • Triple Negative Breast Cancer
  • +5 more
  • Orange, California
  • +6 more
Jan 23, 2023

Triple Negative Breast Cancer, PD-L1 Negative Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Paclitaxel,

Recruiting
  • Triple Negative Breast Cancer
  • PD-L1 Negative
  • Sacituzumab Govitecan-hziy
  • +4 more
  • Anchorage, Alaska
  • +231 more
Jan 17, 2023

Triple Negative Breast Cancer, PD-L1 Positive Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Pembrolizumab,

Recruiting
  • Triple Negative Breast Cancer
  • PD-L1 Positive
  • Sacituzumab Govitecan-hziy
  • +5 more
  • Anchorage, Alaska
  • +245 more
Jan 12, 2023

Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer Trial in United States

Recruiting
  • Non Small Cell Lung Cancer
  • +11 more
  • Denver, Colorado
  • +3 more
Jan 10, 2023

NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)

Recruiting
  • Non-small Cell Lung Cancer
  • +11 more
  • Birmingham, Alabama
  • +32 more
Jan 4, 2023

Melanoma, NSCLC, Bladder Cancer Trial in Worldwide (Autogene cevumeran, Atezolizumab)

Active, not recruiting
  • Melanoma
  • +7 more
  • Scottsdale, Arizona
  • +36 more
Dec 22, 2022

Triple Negative Breast Cancer Trial in Worldwide (Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Concord, California
  • +429 more
Dec 12, 2022

Non Small Cell Lung Cancer, Urothelial Cancer, Ovarian Cancer Trial in United States (XB002, Nivolumab)

Recruiting
  • Non Small Cell Lung Cancer
  • +9 more
  • Saint Louis, Missouri
  • +4 more
Dec 12, 2022

Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative Trial in United States (Atezolizumab, Carboplatin,

Active, not recruiting
  • Triple Negative Breast Cancer
  • +3 more
  • Washington, District of Columbia
  • +5 more
Dec 1, 2022

Squamous Cell Carcinoma of Head and Neck, NSCLC, Hepatocellular Carcinoma Trial in Worldwide (KY1044, KY1044 and atezolizumab)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • +11 more
  • New Haven, Connecticut
  • +12 more
Nov 3, 2022

Breast Cancer, Colorectal Cancer, Ovarian Cancer Trial in United States (ATRC-101, Pembrolizumab, Pegylated liposomal

Recruiting
  • Breast Cancer
  • +15 more
  • ATRC-101
  • +2 more
  • Phoenix, Arizona
  • +10 more
Sep 28, 2022

Ovarian Cancer, Ovarian Tumors, Ovarian Carcinoma Trial in United States (ELU001)

Recruiting
  • Ovarian Cancer
  • +68 more
  • Phoenix, Arizona
  • +8 more
Aug 18, 2022

Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma Trial in United Kingdom, United States

Terminated
  • Pancreatic Adenocarcinoma
  • +13 more
  • San Francisco, California
  • +7 more
Aug 17, 2022

Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer Trial in Worldwide (BT5528,

Recruiting
  • Advanced Solid Tumor Historically Known for High EphA2 Expression
  • +6 more
  • Encinitas, California
  • +27 more
Aug 17, 2022

Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer Trial in United States (navicixizumab+paclitaxel,

Recruiting
  • Colorectal Cancer
  • +3 more
  • navicixizumab+paclitaxel
  • +2 more
  • Hot Springs, Arkansas
  • +5 more
Aug 9, 2022

Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer Trial in Worldwide (PDR001)

Completed
  • Melanoma
  • +4 more
  • PDR001
  • Baltimore, Maryland
  • +40 more
Aug 2, 2022

NSCLC, Renal Cell Cancer, Colorectal Cancer Trial in Australia, United States (CPI-006, CPI-006 + ciforadenant, CPI-006 +

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +12 more
  • Tucson, Arizona
  • +26 more
Aug 1, 2022

NSCLC, Ovarian Cancer, Fallopian Tube Cancer Trial in United States (CART-TnMUC1, Cyclophosphamide, Fludarabine)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • CART-TnMUC1
  • +2 more
  • Phoenix, Arizona
  • +9 more
Jul 18, 2022

Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant Trial in Bethesda, Nashville (TC-510, Fludarabine,

Recruiting
  • Mesothelioma
  • +14 more
  • TC-510
  • +2 more
  • Nashville, Tennessee
    Sarah Cannon Research Institute
Jul 14, 2022

Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, NSCLC Trial in Japan, United States (Datopotamab

Recruiting
  • Hormone Receptor Positive Breast Cancer
  • +2 more
  • Datopotamab Deruxtecan (Dato-DXd)
  • Los Angeles, California
  • +13 more
Jun 21, 2022

Breast Cancer, Triple Negative Breast Cancer, Residual Cancer Trial in United States (Atezolizumab, Sacituzumab govitecan)

Recruiting
  • Breast Cancer
  • +3 more
  • San Francisco, California
  • +8 more
May 25, 2022

Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer Trial in United States (PY314, Combination Therapy: PY314 +

Recruiting
  • Advanced Solid Tumor
  • +8 more
  • PY314
  • Combination Therapy: PY314 + Pembrolizumab
  • Scottsdale, Arizona
  • +12 more
Mar 28, 2022